EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation

    AMSTERDAM, September 22 /PRNewswire/ -- Kiadis Pharma announced today
 that its lead product ATIR(TM) has been granted orphan drug designation
 (ODD) by the European Medicines Agency (EMEA) for the prevention of acute
 Graft versus Host Disease (GvHD) following an allogeneic bone marrow
 transplantation.
 
     "Following the orphan drug designation granted by the FDA for our lead
 product ATIR(TM), this is another important milestone in the development of
 ATIR(TM) as a novel approach which may enable a safe and potentially
 life-saving mismatched bone marrow transplantation as a treatment option
 for end-stage blood cancer patients" says Dr. Manja Bouman, Chief Executive
 Officer of Kiadis Pharma.
 
     The EMEA's orphan drug designation is reserved for new therapies being
 developed to treat life-threatening or chronically debilitating diseases or
 conditions that are relatively rare in the European Union and for which no
 satisfactory therapy is available. The orphan drug designation provides for
 incentives to support research and development, exemption from user fees
 and a ten-year period of market exclusivity in the European Union after
 product approval.
 
     For the complete press release please go to: http://www.kiadis.com/news
 
     About Kiadis Pharma
 
     Kiadis Pharma is an oncology focused pharmaceutical development company
 with three products in different phases of clinical development. The
 company develops products that offer novel treatment options for terminally
 ill cancer patients and address significant unmet medical needs. The key
 focus indication for Kiadis Pharma is limitations and complications of bone
 marrow transplantation procedures performed in blood cancer patients.
 Kiadis Pharma is headquartered in Amsterdam, The Netherlands with
 facilities in Groningen, The Netherlands and Montreal, Canada. For more
 information about Kiadis Pharma, please visit http://www.kiadis.com.
 
 
 

SOURCE Kiadis Pharma

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.